Home Review Articles

Review Articles

To date I have written over 40 review articles, mostly on the topics of cholesterol and lipid metabolism and the clinical pharmacology of lipid regulating drugs.

Those reviews whose pdfs are in the public domain may be downloaded from the Selected PDFspage

References for the review artices are listed below (please select the year from the drop down box) or you can download the full list as a pdf file

2008

  1. Gaw, A. Should we be targeting triglyceride as well as LDL cholesterol in the battle against coronary heart disease? Nature Clinical Practice Cardiovascular Medicine, 5: 438-9, 2008.

2006

  1. Gaw, A. Beyond consent: the potential for atrocity. Journal of the Royal Society of Medicine, 99: 175-177, 2006.

2005

  1. Gaw, A. Rosuvastatin: achieving cholesterol targets. Future Cardiology 1: 289-297, 2005.

2004

  1. Kent JA, Dinnett JA, McIntyre K, Mungall MMB, Ronald ES, Gaw A. Roles for nurses in clinical trials - new challenges, new opportunities. Scottish Nurse 8(9): 30-31, 2004.
  2. Mungall, M.M.B., Gaw, A. Statin therapy in the elderly. Current Opinion in Lipidology, 15: 453-457,2004.
  3. Gaw, A. The care gap: underuse of statin therapy in the elderly. International Journal of Clinical Practice August 2004.
  4. McIntyre KE, Dinnett EM, Mungall MMB, Ronald ES, Kent JA, Gaw A. Selecting investigators in primary care - what to look for; what to avoid. Clinical Research Focus 15(4): 38-43, 2004.

2003

  1. Mungall, M.M.B., Gaw, A., Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? Drugs and Aging 20: 263-275, 2003.
  2. Gaw, A. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovascular Drugs and Therapy 17: 53-62, 2003.
  3. Gaw, A. Coronary heart disease prevention: the role of statin therapy. Scottish Nurse 8: 34-35, 2003.
  4. Mungall, M.M.B., Gaw, A. Statin use: what is the evidence base? Geriatric Medicine November, 2003.

2002

  1. Gaw, A. A new reality: achieving cholesterol-lowering goals in clinical practice. Atherosclerosis Suppl 2: 5-11, 2002.
  2. Gaw, A. Primary prevention: a simple, effective means of risk reduction. International Journal of Clinical Practice Suppl 130: 6-12, 2002.
  3. Shepherd, J. and Gaw, A. The Anatomy of a Clinical Trial: The West of Scotland Coronary Prevention Study. Medical Principles and Practice.2: 17-30, 2002.

2001

  1. Gaw, A. Simvastatin: building on success. Hospital Medicine, 62: 29-32, 2001.
  2. Pedersen, T. and Gaw, A. Statins - similarities and differences. American Journal of Managed Care 7 (5Suppl): S132-S137, 2001.
  3. Gaw, A. Healthy ageing: addressing acute coronary syndrome? European Heart Journal Supplements 3 (Suppl N): N11-N15, 2001.
  4. Gaw, A. The statin benefit. Scottish Primary Care 12: 12-13,2001.

2000

  1. Gaw, A., and Packard C.J. At what level of coronary heart disease risk should a statin be prescribed? Current Opinion in Lipidology, 11: 363-367, 2000.

1998

  1. Gaw, A., and Shepherd, J.: Identifying and treating those at risk: new evidence from the West of Scotland Coronary Prevention Study. Cardiovascular Risk Factors 8: 12-19, 1998.
  2. Gaw, A. Evidence based approach for the management of mixed hyperlipidaemia. Atherosclerosis, 137 (Suppl). 97-100, 1998.

1997

  1. Gaw, A. How are statins best applied? Costs & Options in Hyperlipidaemia, Issue 13, 1997.

1996

  1. Gaw, A. Lipoprotein (a): molecular genetics and cardiovascular risk. Fundacja Rozwoju Diagnostyki Laborattoryjnej (Journal of Polish Society of Laboratory Diagnostics), 1: 101-117, 1996.
  2. Cowan, R.A., O'Reilly, D. St.J., and Gaw, A. How to diagnose hypercalcaemia I. Student BMJ 4: 95-97, 1996.
  3. Cowan, R.A., O'Reilly, D. St.J., and Gaw, A. How to diagnose hypercalcaemia-II. Hypercalcaemia of malignancy. Student BMJ 4: 142-143, 1996.
  4. Gaw, A., and Demant, T. Apolioprotein-B metabolism in primary and secondary hyperlipidaemias. Current Opinion in Lipidology 7: 149-154, 1996.
  5. Gaw, A. Lipoprotein metabolism: bimonthly review. Current Opinion in Lipidology 7: U49-U56, 1996.

1995

  1. Gaw, A., Packard, C.J. and Shepherd, J.: Fibrates: pharmacology and clinical application. Cardiovascular Risk Factors. 5: 45-56, 1995.
  2. O'Reilly, D. St.J., Cowan, R.A., and Gaw, A. The interpretation of thyroid function tests. Student BMJ 3: 447-449, 1995.

1994

  1. Hobbs, H.H., Chiesa, G., Gaw, A., Lawn, R., Maika, S., Koschinsky, M., and Hammer, R.: Apo (a) expression in transgenic mice. Annals of the New York Academy of Science 714: 231-236, 1994.
  2. Gaw, A. and Hobbs, H.H.: Molecular genetics of Lp(a) - new pieces to the puzzle. Current Opinion in Lipidology 5: 149-155, 1994.

1993

  1. Shepherd, J., Caslake, M., Gaw, A., Griffin, B., Lindsay, G., and Packard, C. Atherogenicity of triglyceride rich lipoproteins. Annales de Biologie Clinique 51: 260-262, 1993

1992

  1. Gaw, A., Packard, C.J., and Shepherd, J.: VLDL and LDL turnover: methods and clinical application. Current Opinion in Lipidology . 3: 384-388, 1992.
  2. Gaw, A.: New lipid lowering drugs. G.P. Update April 669-677, 1992.

1991

  1. Gaw, A., and Shepherd, J.: Fibric acid derivatives. Current Opinion in Lipidology 2: 39-42, 1991.
  2. Shepherd, J., Griffin , B., Caslake, M., Gaw, A., and Packard, C.: The influence of fibrates on lipoprotein metabolism. Atherosclerosis Reviews. 22: 163-169, 1991.

1990

  1. Gaw, A., and Shepherd, J.: Combination drug therapy for hyperlipidaemia. Journal of Drug Development 3(Suppl. 1): 227-231, 1990.
  2. Gaw, A., Griffin, B.A., Gaffney, D., Caslake, M.J., Packard, C.J., and Shepherd, J.: Genetic and environmental modulation of low-density lipoprotein catabolism. Biochemical Society Transactions 18: 1072-1074, 1990.

1989

  1. Gaw, A. and McKean, C.M.: Therapeutic drug monitoring. (A series of nine illustrated one page articles published monthly) ACB News Sheet, Feb-Oct 1989.